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Turner syndrome (TS) is one of the most
common sex chromosomal disorders
affecting 25 to 50 females out of 100,000
females (1). Most women with TS are infer-
tile because of an accelerated depletion of
ovarian follicles causing premature ovarian
insufﬁciency (POI). Among all main char-acteristics of TS, including short stature, cardiovascular mal-
formations and hearing problems, women with TS report that
POI and infertility are the greatest challenges that they face
(2). The inability to have biological children remains a central
source of pain and hardship for TS women of all ages across
their lifespan (2).
Naturally conceived pregnancies occur in only 5% to 8%
of women with TS being most prevalent in women with
mosaic TS (3–5). However, during the last decades, assisted
reproductive technologies (ART) have, also for women with
TS, provided excellent opportunities to conceive and give
birth. Live-birth rates after ART with autologous oocytes is
of limited success (6), but treatment with oocyte donation
(OD) is a realistic treatment option for women with TS.rticle with its authors and other readers at https://www.
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Pregnancy in women with TS is fraught
with risk. Foremost is the high risk of death
from aortic dissection or rupture, due to the
substantial cardiovascular changes that
occur in pregnancy. Turner syndrome is a
condition that usually results in ovarian
insufﬁciency prior to the age of puberty.As such, only 5% to 6% of women with TS will ever achieve
a spontaneous pregnancy (5). Therefore, it is extremely difﬁ-
cult to estimate thematernal morbidity andmortality in spon-
taneous pregnancies in TS.
As would be expected, OD results in similar pregnancy
rates for women with TS compared to those treated with OD
for other reasons (17). With growing numbers of pregnancies
in this population we are better able to evaluate the risk of
pregnancy in a condition known to have a high incidence
of left-sided heart defects and aortopathy, as well as other
associated medical conditions (1). The medical literature
now reveals an alarming rate of fatal maternal aortic dissec-
tion or rupture in pregnancy, although the exact magnitude of
that risk is still not accurately measured due to the relatively
small number of pregnancies studied, in what is still a fairlysers/16110-fertility-and-sterility/posts/49612-28405
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Fertility and Sterility®Following OD, the clinical pregnancy rate per embryo
transfer (ET) in women with TS varies between 16% and
40%, which is like that of other OD recipients with POI (1). To
achieve high success rates and low miscarriage rates adequate
hormonal replacement therapy is of utmost importance. For
young women with TS and POI who consider OD treatment
in the future, the endometrium should be prepared well in
advance, with estradiol-based hormonal replacement therapy
to achieve an appropriate uterine size and development (7).
In women with TS, maternal morbidity and mortality
caused by the generally increased cardiovascular demands
during pregnancy has raised much concern over the years.
Congenital heart disease occurs in up to 50% of girls with
TS, including a high incidence of bicuspic aortic valve, coarc-
tation of the aorta and underlying vasculopathy that can lead
to rare but often life-threatening dissection of aorta. The
debate has been facilitated by several reports of aortic dissec-
tions and deaths in pregnant women with TS that have been
published since the late 1990s (8–13). A Swedish national
registry study of 124 child-bearing women with TS karyotype
also identiﬁed a high rate of circulatory and endocrine dis-
eases as well as of aortic aneurysm, but with no maternal
deaths during a 10-year follow-up period (14).
After OD, the risk of having a hypertensive disorder of
pregnancy (HDP) is increased in women with TS compared
to OD recipients treated for other medical indications. The re-
ported incidence of HDP is 35–67% in singleton pregnancies
in women with TS (12, 15–20) compared to 13% to 39% in OD
recipients in general (21).
The question is: Should all women with TS categorically
be banned from ART treatment because of obstetric risks?
Do we consider that all women with TS should be denied
the opportunity to carry a pregnancy and give birth to a child?
Do all these women need a surrogacy treatment? In our
opinion, the answer is no. We believe that women with TS
can receive ART treatment and give birth, if certain safety
conditions are secured.
In the Nordic countries, women with TS have received OD
since the early 1990s. In 1992–2011, altogether 106 women
with TS had 122 deliveries and gave birth to 131 children after
having received donated oocytes (20). The twin rate was low
(7.4%) and these twin pregnancies were observed in the early
reports before single embryo transfer became the routine pol-
icy in ART already in the late 1990s. Of the recipients, 44%
had a 45,X karyotype.
When the ﬁrst OD treatments in women with TS were per-
formed in Finland three decades ago, the knowledge about
cardiovascular pregnancy risks was scarce. Hence, in the
Nordic cohort of 106 childbearing womenwith TS, ten women
had a known cardiac defect before pregnancy, and only one-
forth had an echocardiography done during pregnancy (20).
In total, HDP was observed in 35% of these pregnancies.
Potentially life-threatening complications occurred in four
patients, but no maternal deaths were reported. NeonatalVOL. 112 NO. 2 / AUGUST 2019rare occurrence. In 2003we published a study that estimated a
maternal mortality rate of 2% from aortic dissection or
rupture in women with TS who conceived through oocyte
donation in the U.S. (22). This estimate was supported in a
subsequent study by Chevalier et al. (12) The magnitude of
this risk is staggering when you consider that if an obstetri-
cian cared for 300 women with this level of risk in a year, 6
of them would die.
Aortic dissection or rupture is known to be a signiﬁcant
risk for girls and women with TS outside of pregnancy, at
any age, with or without risk factors (27–29). This is
presumably related to an inherent aortopathy affecting the
great vessels. Several publications have reported autopsy
ﬁndings of aortic wall cystic medial necrosis, as is seen in
Marfan syndrome (28). Weinsaft et al. (30) studied the risk
of aortic dissection in 1,991 patients with genetically
mediated aortic aneurysms and concluded that these
patients are at increased risk of aortic dissection, even in
the context of minimal aortic dilation. This study included
101 women with TS, two of whom had an aortic dissection,
outside of pregnancy (30). The increased cardiovascular
demands of pregnancy put women with TS at even greater
risk (31). These demands are increased further in a multiple
pregnancy with an estimated 5-fold higher risk of maternal
mortality compared to a singleton pregnancy with a 110-
fold increase in risk over the general population of the U.S.
of 0.018% in 2014 (32, 33). Furthermore, pregnancy not
only increases the risk of aortic dissection/rupture during
the gestation but also seems to increase the risk subsequent
to pregnancy, presumably due to aortic wall compromise
that originated during pregnancy (28, 34).
The cardiology literature provides an understanding of
risk factors that increase the probability of aortic dissection
in the general population, as well as in TS. Factors that are
known to increase the risk of aortic dissection are aortic dila-
tion, bicuspid aortic valve (BAV), history of coarctation of the
aorta (repaired or not) and hypertension and the presence of
an elongated transverse aorta (1, 35). It is important to note
that there does not seem to be a phenotype that is
protective, as cases of fatal aortic dissection/rupture have
been reported in women with no known risk factors (1, 29,
36–39). Several studies have now shown reduced aortic
distensibility in mosaic and non-mosaic TS, as well as
increased central diastolic blood pressure, compared to sex
and age matched controls (40, 41). This may explain the
persisting high risk of aortic dissection in women with no
other identiﬁable risk factors.
A Swedish registry study found that there was not a pro-
tective genotype for aortic dissection or aortic aneurysm (14,
42). Researchers in Portland, Oregon, appear to have
identiﬁed at least one gene associated with BAV and
aortopathy. The gene tissue inhibitor of matrix
metalloproteinase (TIMP) 3 was shown to be associated with
BAV and aortic dilation and that TIMP1 appears to be the221
PRO: Pregnancies in women with Turner
syndrome should always be preceded by
intensive screening (continued)
CON: Pregnancies in women with Turner
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FERTILE BATTLEoutcomes were reassuring; the mean birth weight of singleton
babies was 3150 g, the preterm birth rate 8.0% and low birth
rate was 8.8% in singletons. Major birth defects were found in
3.8% of the children. The perinatal mortality was 2.3% (3/
131), including a set of extremely preterm twins (20). The
Nordic neonatal data are comparable to outcomes after OD
in general (21).
In studies reporting serious cardiac complications or
aortic dissection during pregnancy in women with TS, a mi-
nority went through a cardiac evaluation before ART (12,
22). In the two largest reports to-date, including 93 and 106
women, only 38% and 49% had a pre-pregnancy echocardi-
ography carried out (12, 20). If there had been intensive
pre-pregnancy cardiovascular evaluation, women facing se-
vere cardiovascular risk factors would probably have had
denial of OD treatment. Based on the knowledge that we
have today, there are several strategies to minimize risks for
maternal morbidity related to these pregnancies.
Firstly, all women with TS need to undergo an intensive
pre-pregnancy health screening explained in the recently
published guidelines for the care of girls and women with
TS (1). Brieﬂy, heart echocardiography and magnetic reso-
nance imaging need to be done within two years before
planned pregnancy or ART. Spontaneous conception and
ART should be avoided in case of an ascending aortic size in-
dex of >2.5 cm/m2 or an ascending aortic size index 2.0 to
2.5 cm/m2 with associated risk factors for aortic dissection,
which include bicuspid aortic valve, elongation of the trans-
verse aorta, coarctation and hypertension. Women with a his-
tory of aortic dissection should be advised against pregnancy
and denied OD treatment (1).
Secondly, of utmost importance is that the only accept-
able embryo transfer strategy is single embryo transfer. Mul-
tiple embryo transfer should never be performed in women
with TS as maternal and neonatal complications are tremen-
dously increased in twin pregnancies, e.g. the risk of aortic
dissection is ﬁve-fold higher in multiple pregnancies
compared to singletons (19).
Thirdly, pregnant women with TS should be taken care of
by a multidisciplinary team including maternal fetal medicine
specialists, and cardiologists with experience in managing
women with TS (1, 23). Echocardiography should be done at
least once during pregnancy and in cases with risk factors at
4- to 8-week intervals during pregnancy and during the ﬁrst
6months postpartum. Blood pressure need to be kept on a level
less than 135/85 mmHg in all pregnant women with TS (1).
However, it is be kept inmind that womenwith TS need to
be informed that all precautions and optimal caretaking dur-
ing pregnancy do not guarantee a positive outcome, as serious
maternal complications have happened also without identiﬁ-
able risks (11–13).
But what other options than OD do these women have?
Unfortunately, not many. Adoption or surrogacy have been
suggested as primary options for TS women to become222Xp chromosome sensitizing factor for both BAV and
aortopathy in TS. The study was able to show that the risk
is higher with only a single copy of the TIMP1 gene but
that BAV and aortic disease were seen in mosaic individuals
(43).
Due to the phenotypic and genotypic variability in TS,
pregnancy may be lower risk in some individuals than in
others. In a study of a database for rare growth disorders
from the French Ministry of Health, Bernard et al. (5) report
52 spontaneous pregnancies in 27 women, from 480 patients
with TS. There where no cases of aortic dissection or other car-
diac complication in this small cohort of women (5). It may be
that the risk of dying from aortic dissection in pregnancy is
lower in women with no identiﬁed cardiac risk factors but it
must be understood that the evaluation of risk factors for
aortic dissection in TS is still being elucidated and we have
yet to fully comprehend how to adequately assess the risk
of aortic dissection prior to pregnancy. Gravholt and The In-
ternational Turner Syndrome Consensus Group published
clinical practice guidelines in 2016 (1). These guidelines
recommend that pregnancy be avoided in women with a his-
tory of aortic dissection or if there is an increased aortic size
index, especially if associated with BAV, elongation of the
transverse aorta, coarctation of the aorta or hypertension.
Cadoret et al. (44) recently published a retrospective study
of pregnancy outcomes in women with TS who conceived
following the introduction of French guidelines for the man-
agement of patients with TS, before, during and after preg-
nancy (23). They compare 62 patients since 2009 to 93
patients prior to 2009, pregnant through oocyte donation.
The cohort since 2009 had a signiﬁcantly lower incidence of
monosomy karyotype and a signiﬁcantly higher occurrence
of preconception evaluation and detailed cardiac evaluation.
They subsequently showed a signiﬁcantly lower incidence of
hypertensive disorders in pregnancy, preeclampsia and pre-
maturity. There were no maternal deaths in their cohort.
The inference from their conclusion is that the introduction
of the guidelines led to a change in practice that thereafter
improved the safety of pregnancy. However, despite the
guidelines, only 79% of their cohort had preconception eval-
uation, only 63% had a known cardiac diameter, and only
50% had an angio magnetic resonance imaging. In addition,
only 45% had a cardiac ultrasound within 2 months post par-
tum. Therefore it is possible that the lack of maternal mortal-
ity in this small cohort is simply by chance.
Based on the available literature, women with TS desiring
pregnancy need to have exhaustive screening and pregnancy
should be avoided if risk factors for aortic dissection are iden-
tiﬁed. Those without risk factors still need to be fully aware of
their increased risk of death in pregnancy from aortic dissec-
tion or rupture, in addition to their approximately 30% to
62% risk of hypertensive disorders of pregnancy, predomi-
nantly preeclampsia (45). Bodri et al. (17) found that this
high rate of hypertensive disorders in pregnancy was notVOL. 112 NO. 2 / AUGUST 2019
PRO: Pregnancies in women with Turner
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Fertility and Sterility®mothers. In general, these alternatives are very complicated to
follow at least in the Nordic countries. The adoption author-
ities might not consider women with TS as optimal candidates
for adoption, because of the health concerns related to the TS
diagnosis.
What about surrogacy? In case of contraindications to
carry a pregnancy, surrogate treatment is a good option.
However, surrogacy is illegal in many parts of the world
including most European countries, e.g. all Nordic countries.
Searching for commercial surrogacy treatment abroad in
Eastern Europe, Asia, or North America is often beyond all
practical and economic realities for these women.
Many Western countries has made surrogacy treatment
illegal because of health concerns related to the surrogate,
welfare of the child, and possible risks of exploitation of
women acting as a gestational carrier. A pregnancy is never
without risks, even for a healthy womanwith previous normal
pregnancies and deliveries. Serious obstetric complications,
such as peripartum hysterectomies, have been reported in
gestational carriers (24).
There is growing evidence that fertility preservation with
oocyte cryopreservation appears to be an option for young
women with TS who retain ovarian function after puberty.
It has been possible to cryopreserve mature oocytes after
ovarian stimulation and oocyte retrieval (25). One report
also indicates that oocytes collected from women with TS
might be cytogenetically normal (26). Candidates for oocyte
vitriﬁcation need to have counseling regarding health re-
quirements for usage of such oocytes in the future, so that
they try to have a healthy lifestyle to maintain their health
as good as possible to be able to carry a pregnancy (25).
Infertility has been reported as the major concern for girls
and women with TS. Treating these women with OD requires
intensivemedical screening and counseling of associatedmed-
ical risks. Doctors should not be afraid of denial of treatment
when the maternal risks are too high. However, in addition
to safety aspects, the physician must also consider the strong
wishes and the reproduction rights of his/her patients.Without
obvious medical contraindications and after counseling, these
women should not be denied the chances to have a much-
wanted pregnancy naturally conceived or by ART. Finally,
we need to emphasize that the single embryo transfer policy
should be strictly followed in women with TS. This is crucial
for the safety of the mothers and the babies born.VOL. 112 NO. 2 / AUGUST 2019explained by maternal age, multiple gestation or oocyte
donation. In the Bernard et al. (5) series of spontaneous preg-
nancies, there was a 13.3% rate of hypertensive disorders of
pregnancy/preeclampsia, which compares to an expected
rate of hypertensive disorders of pregnancy/preeclampsia of
2.8% based on the average age of this cohort. They are also
at increased risk for liver diseases, gestational diabetes and
thyroid dysfunction, spontaneous miscarriage, caesarean sec-
tion, preterm delivery and low birth weight (5, 17, 31, 46).
Prior to the introduction of oocyte donation, the vast ma-
jority of womenwith TS whowanted children chose adoption.
This choice is still, of course, an option. The most widely rec-
ommended fertility treatment for women with TS and for a
multitude of women who cannot carry a child, is to partner
with a gestational carrier. While logistically challenging, a
gestational carrier allows for the use of the patient's partner's
sperm (if applicable) and allows for the parents' involvement
from the time of conception. Often it also leads to a lasting
relationship between the gestational carrier and the intended
parent(s).
In summary, several studies have shown a maternal mor-
tality for pregnant women with TS as high as 2%. Recent se-
ries have fortunately not reported deaths for pregnant women
with TS, inferring that this was the result of screening out
those women with risk factors. Recent series, however, are
small and include a number of patients not screened. The
lack of deaths in series of small sample size may be the result
of chance alone. In addition, the registry studies published in
recent years are hampered by the paucity of available detail
on the medical histories of the women studied and by the
lower standard of medical diagnostics and care of the past de-
cades. There is also inherent selection bias and detection bias
that occurs in hospital-based studies like these (42). Guide-
lines created by Gravholt et al. (1) recommend against preg-
nancy for women with identiﬁed risk factors for aortic
dissection. Given that a safe phenotype of TS has not been
identiﬁed, cautious counselling of patients who have no iden-
tiﬁable risk factors still needs to occur and must include a dis-
cussion about the potential high risk of death and the
remaining high rates of hypertensive disease and morbidity
of pregnancy in these apparently lower risk individuals. While
hopefully comprehensive screening will signiﬁcantly lower
maternal mortality, counseling lower-risk patients that preg-
nancy is an option may, unfortunately, be tempting fate.223
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